

Please type a plus sign (+) inside this box

10-31-99. OMB 0651-0031

DEPARTMENT OF COMMERCE

PTO/SB/08A (10-96)

Approved for use through

Patent and Trademark Office: U.S.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				COMPLETE IF KNOWN	
				Application Number	09/308,150
				Filing Date	May 13, 1999
				First Named Inventor	Van Venrooij
				Group Art Unit	UNKNOWN 1644
				Examiner Name	Amy DeClouy
Sheet	1	of	2	Attorney Docket Number	30394-1027

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	0 511 116	A	Clonatec S.A.	28 Oct 1992		Not in English
		FR	2 7522 842	A1	Biomerieux-sa-Societe	6 Mar 1998		Not in English

Examiner Signature	Amy DeClouy	Date Considered	1-24-01
-----------------------	-------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[F:\FORMS\PAT\Los&Stigter-VanVenrooij-1449p1.PTO.doc] 30394-1027

1. Unique citation designation number. 2. See attached Kinds of U.S. Patent Documents. 3. Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.



COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				COMPLETE IF KNOWN			
				Application Number		09/308,150	
				Filing Date		May 13, 1999	
				First Named Inventor		VAN VENROOIJ	
				Group Art Unit		UNKNOWN 1644	
				Examiner Name		Amy DeCloux	
Sheet	2	of	2	Attorney Docket Number		30394-1027	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AD		GAN, SONG-QING, "Organization, Structure, and Polymorphisms of the Human Profilaggrin Gene," <i>Biochemistry</i> , Vol. 29, No. 40, pp 9432-9440 (9 October 1990)	
AD		HOET, R.M.A., et al., "Antiperinuclear Factor, a Marker Autoantibody for Rheumatoid Arthritis: Colocalixstion of the Perinuclear Factor and Profilaggrin," <i>Annals of the Rheumatic Diseases</i> , Vol. 50, No. 9, Loden, Great Britain (September 1991) p611-614	
AD		MISAKI, Y., et al., "The 56K Autontigen is Identical to Human Annexin XI", <i>Journal of Biological Chemistry</i> , Vol. 269, No. 6, Baltimore MD, pp 4240-4246 (February 11, 1994)	
AD		SEGGAG, M., et al., "The Antiperinuclear Factor and the So-Called Antikeratin antibodies Are the Same Rheumatoid Arthritis - Specific Autoantibodies," <i>Journal of Clinical investigation</i> , Vol. 95, No. 6, New York NY (June 1995) p2672-2679	
AD		SIMON, M., et al., "The Cyokeratin Filament-Aggregating Protein Filaggrin is the Target of the So-called 'Antikeratin Antibodies,' Autoantibodies Specific for Rheumatoid Arthritis," <i>Journal of Clinical Investigation</i> , Vol. 92, No. 3, pp 1387-1393 New York NY (September 1993)	
AD		SHELLENKENS, G.A., et al., "The Modified Arginine residue Citrulline is the Major Constituent of Epitopes Recognized by Autoantibodies in Sera from Rheumatoid Arthritis Patients," <i>Arthritis and Rheumatism</i> , vol. 40, No. 9, pg. S276, New York NY (8-12 November 1997)	

Examiner Signature	Amy DeCloux	Date Considered	1-24-01
-----------------------	-------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[F:\FORMS\PAT\Los&Stigter-VanVenrooij-1449p2.PTO.doc] 30394-1027

¹ Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.